Search

Your search keyword '"Zijlstra, J. M."' showing total 93 results
Start Over Author "Zijlstra, J. M."
93 results on '"Zijlstra, J. M."'

1. Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma

Author

Eertink, J. J., Zwezerijnen, G. J. C., Heymans, M. W., Pieplenbosch, S., Wiegers, S. E., Dührsen, U., Hüttmann, A., Kurch, L., Hanoun, C., Lugtenburg, P. J., Barrington, S. F., Mikhaeel, N. G., Ceriani, L., Zucca, E., Czibor, S., Györke, T., Chamuleau, M. E. D., Hoekstra, O. S., de Vet, H. C. W., Boellaard, R., and Zijlstra, J. M.

Published
2023
Full Text
View/download PDF

3. Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma

Author

MS Radiotherapie, Cancer, Verpleegkundig specialisten & PA's, Geurts, Y M, Neppelenbroek, S I M, Aleman, B M P, Janus, C P M, Krol, A D G, van Spronsen, D J, Plattel, W J, Roesink, J M, Verschueren, K M S, Zijlstra, J M, Koene, H R, Nijziel, M R, Schimmel, E C, de Jongh, E, Ong, F, Te Boome, L C J, van Rijn, R S, Böhmer, L H, Ta, B D P, Visser, H P J, Posthuma, E F M, Bilgin, Y M, Muller, K, van Kampen, D, So-Osman, C, Vermaat, J S P, de Weijer, R J, Kersten, M J, van Leeuwen, F E, Schaapveld, M, MS Radiotherapie, Cancer, Verpleegkundig specialisten & PA's, Geurts, Y M, Neppelenbroek, S I M, Aleman, B M P, Janus, C P M, Krol, A D G, van Spronsen, D J, Plattel, W J, Roesink, J M, Verschueren, K M S, Zijlstra, J M, Koene, H R, Nijziel, M R, Schimmel, E C, de Jongh, E, Ong, F, Te Boome, L C J, van Rijn, R S, Böhmer, L H, Ta, B D P, Visser, H P J, Posthuma, E F M, Bilgin, Y M, Muller, K, van Kampen, D, So-Osman, C, Vermaat, J S P, de Weijer, R J, Kersten, M J, van Leeuwen, F E, and Schaapveld, M

Published
2024

4. R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: A propensity matched population-based study

Author

MS Hematologie, Cancer, Infection & Immunity, Al-Sarayfi, D., Brink, M., Chamuleau, M. E.D., Brouwer, R., van Rijn, R. S., Issa, D., Deenik, W., Huls, G., Mous, R., Vermaat, J. S.P., Diepstra, A., Zijlstra, J. M., van Meerten, T., Nijland, M., MS Hematologie, Cancer, Infection & Immunity, Al-Sarayfi, D., Brink, M., Chamuleau, M. E.D., Brouwer, R., van Rijn, R. S., Issa, D., Deenik, W., Huls, G., Mous, R., Vermaat, J. S.P., Diepstra, A., Zijlstra, J. M., van Meerten, T., and Nijland, M.

Published
2024

5. Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma

Author

Geurts, Y. M., Neppelenbroek, S. I.M., Aleman, B. M.P., Janus, C. P.M., Krol, A. D.G., van Spronsen, D. J., Plattel, W. J., Roesink, J. M., Verschueren, K. M.S., Zijlstra, J. M., Koene, H. R., Nijziel, M. R., Schimmel, E. C., de Jongh, E., Ong, F., te Boome, L. C.J., van Rijn, R. S., Böhmer, L. H., Ta, B. D.P., Visser, H. P.J., Posthuma, E. F.M., Bilgin, Y. M., Muller, K., van Kampen, D., So-Osman, C., Vermaat, J. S.P., de Weijer, R. J., Kersten, M. J., van Leeuwen, F. E., Schaapveld, M., Geurts, Y. M., Neppelenbroek, S. I.M., Aleman, B. M.P., Janus, C. P.M., Krol, A. D.G., van Spronsen, D. J., Plattel, W. J., Roesink, J. M., Verschueren, K. M.S., Zijlstra, J. M., Koene, H. R., Nijziel, M. R., Schimmel, E. C., de Jongh, E., Ong, F., te Boome, L. C.J., van Rijn, R. S., Böhmer, L. H., Ta, B. D.P., Visser, H. P.J., Posthuma, E. F.M., Bilgin, Y. M., Muller, K., van Kampen, D., So-Osman, C., Vermaat, J. S.P., de Weijer, R. J., Kersten, M. J., van Leeuwen, F. E., and Schaapveld, M.

Abstract

Background: The introduction of rituximab significantly improved the prognosis of diffuse large B-cell lymphoma (DLBCL), emphasizing the importance of evaluating the long-term consequences of exposure to radiotherapy, alkylating agents and anthracycline-containing (immuno)chemotherapy among DLBCL survivors. Methods: Long-term risk of subsequent malignant neoplasms (SMNs) was examined in a multicenter cohort comprising 2373 5-year DLBCL survivors treated at ages 15-61 years in 1989-2012. Observed SMN numbers were compared with expected cancer incidence to estimate standardized incidence ratios (SIRs) and absolute excess risks (AERs/10 000 person-years). Treatment-specific risks were assessed using multivariable Cox regression. Results: After a median follow-up of 13.8 years, 321 survivors developed one or more SMNs (SIR 1.5, 95% CI 1.3-1.8, AER 51.8). SIRs remained increased for at least 20 years after first-line treatment (SIR ≥20-year follow-up 1.5, 95% CI 1.0-2.2, AER 81.8) and were highest among patients ≤40 years at first DLBCL treatment (SIR 2.7, 95% CI 2.0-3.5). Lung (SIR 2.0, 95% CI 1.5-2.7, AER 13.4) and gastrointestinal cancers (SIR 1.5, 95% CI 1.2-2.0, AER 11.8) accounted for the largest excess risks. Treatment with >4500 mg/m2 cyclophosphamide/>300 mg/m2 doxorubicin versus ≤2250 mg/m2/≤150 mg/m2, respectively, was associated with increased solid SMN risk (hazard ratio 1.5, 95% CI 1.0-2.2). Survivors who received rituximab had a lower risk of subdiaphragmatic solid SMNs (hazard ratio 0.5, 95% CI 0.3-1.0) compared with survivors who did not receive rituximab. Conclusion: Five-year DLBCL survivors have an increased risk of SMNs. Risks were higher for survivors ≤40 years at first treatment and survivors treated with >4500 mg/m2 cyclophosphamide/>300 mg/m2 doxorubicin, and may be lower for survivors treated in the rituximab era, emphasizing the need for studies with longer follow

Published
2024

6. Cost-utility of an eHealth application ‘Oncokompas’ that supports cancer survivors in self-management: results of a randomised controlled trial

Author

van der Hout, A., Jansen, F., van Uden-Kraan, C. F., Coupé, V. M., Holtmaat, K., Nieuwenhuijzen, G. A., Hardillo, J. A., de Jong, R. J. Baatenburg, Tiren-Verbeet, N. L., Sommeijer, D. W., de Heer, K., Schaar, C. G., Sedee, R. J. E., Bosscha, K., van den Brekel, M. W. M., Petersen, J. F., Westerman, M., Honings, J., Takes, R. P., Houtenbos, I., van den Broek, W. T., de Bree, R., Jansen, P., Eerenstein, S. E. J., Leemans, C. R., Zijlstra, J. M., Cuijpers, P., van de Poll-Franse, L. V., and Verdonck-de Leeuw, I. M.

Published
2021
Full Text
View/download PDF

7. R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study

Author

Al‐Sarayfi, D., primary, Brink, M., additional, Chamuleau, M. E. D., additional, Brouwer, R., additional, van Rijn, R. S., additional, Issa, D., additional, Deenik, W., additional, Huls, G., additional, Mous, R., additional, Vermaat, J. S. P., additional, Diepstra, A., additional, Zijlstra, J. M., additional, van Meerten, T., additional, and Nijland, M., additional

Published
2023
Full Text
View/download PDF

9. Risk of male breast cancer after Hodgkin lymphoma

Author

van Leeuwen, F. E., Nijdam, A., Aleman, B. M. P., de Boer, J. P., Janus, C. P. M., Mutsaers, P. G. N. J., So-Osman, C., Zijlstra, J. M., Meijer, O. W. M., Rademakers, S. E., Krol, A. D. G., Kersten, M. J., Tonino, S. H., Jalink, M., Daniëls, L. A., van Spronsen, D. J., van der Maazen, R. W. M., Loonen, J., Roesink, J. M., Oostvogels, R., de Weijer, R., Buter, D., de Boer, A., Aarsman, K. M., Oudbier, C. W., Nijziel, M. R., van den Berg, M., Verschueren, K., Schippers, M., Boersma, R. S., Issa, D. E., Plattel, W. J., Stedema, F. G., Koene, H. R., Raymakers, E. R. P. M., Schimmel, E., van Hezewijk, M., Bouma, P., Muller, K., Siemes, C., van der Spek, J. M., Ong, F., Jonkman, A., de Jongh, E., Sprangers, S., Kortleve, J. P., Vermeiden, C. M., Ta, B., Vercoulen, L., Paulissen, J., Posthuma, E. F. M., Brouwer, R. E., Soechit, S., van der Wiel, M., Böhmer, L., Bilgin, M. Y., Kuipers, S., Houmes, M., te Boome, L., Gommers, S., de Vries, Simone, Krul, Inge M., Schaapveld, Michael, Janus, Cecile P. M., Rademakers, Saskia E., Roesink, Judith M., Nijziel, Marten R., Bilgin, Yavuz M., Aleman, Berthe M. P., and van Leeuwen, Flora E.

Published
2023
Full Text
View/download PDF

11. Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP

Author

Driessen, J., Kersten, M. J., Visser, L., van den Berg, A., Tonino, S. H., Zijlstra, J. M., Lugtenburg, P. J., Morschhauser, Franck, Hutchings, M., Amorim, S., Gastinne, T., Nijland, M., Zwezerijnen, G. J. C., Boellaard, R., de Vet, H. C. W., Arens, A. I. J., Valkema, R., Liu, R. D. K., Drees, E. E. E., de Jong, D., Plattel, W. J., Diepstra, A., Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Graduate School, CCA - Cancer Treatment and Quality of Life, Clinical Haematology, CCA - Imaging and biomarkers, Stem Cell Aging Leukemia and Lymphoma (SALL), Translational Immunology Groningen (TRIGR), Hematology, Radiology & Nuclear Medicine, CCA - Cancer Treatment and quality of life, Radiology and nuclear medicine, Amsterdam Neuroscience - Brain Imaging, Epidemiology and Data Science, APH - Methodology, and Pathology

Subjects
Brentuximab Vedotin, Cancer Research, Immunoconjugates, [SDV]Life Sciences [q-bio], Hematology, Prognosis, Hodgkin Disease, Oncology, SDG 3 - Good Health and Well-being, Positron-Emission Tomography, Humans, Prospective Studies, Neoplasm Recurrence, Local, Vitamin D, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], Stem Cell Transplantation
Abstract

Contains fulltext : 287833.pdf (Publisher’s version ) (Closed access) Risk-stratified treatment strategies have the potential to increase survival and lower toxicity in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients. This study investigated the prognostic value of serum (s)TARC, vitamin D and lactate dehydrogenase (LDH), TARC immunohistochemistry and quantitative PET parameters in 65 R/R cHL patients who were treated with brentuximab vedotin (BV) and DHAP followed by autologous stem-cell transplantation (ASCT) within the Transplant BRaVE study (NCT02280993). At a median follow-up of 40 months, the 3-year progression free survival (PFS) was 77% (95% CI: 67-88%) and the overall survival was 95% (90-100%). Significant adverse prognostic markers for progression were weak/negative TARC staining of Hodgkin Reed-Sternberg cells in the baseline biopsy, and a high standard uptake value (SUV)mean or SUVpeak on the baseline PET scan. After one cycle of BV-DHAP, sTARC levels were strongly associated with the risk of progression using a cutoff of 500 pg/ml. On the pre-ASCT PET scan, SUVpeak was highly prognostic for progression post-ASCT. Vitamin D, LDH and metabolic tumor volume had low prognostic value. In conclusion, we established the prognostic impact of sTARC, TARC staining, and quantitative PET parameters for R/R cHL, allowing the use of these parameters in prospective risk-stratified clinical trials. Trial registration: NCT02280993.

Published
2022

12. Reproducibility of FDG PET-CT liver SUV uptake metrics as reference or normalisation factor

Author

Zwezerijnen, G., Eertink, J. J., Ferrandez-Ferrandez, M. C., Wiegers, S. E., Burggraaff, C. N., Lugtenburg, P. J., De Vet, H. C. W., Zijlstra, J. M., Boellaard, R., Radiology and nuclear medicine, Hematology laboratory, Internal medicine, Epidemiology and Data Science, APH - Methodology, Hematology, CCA - Cancer Treatment and quality of life, CCA - Imaging and biomarkers, and Amsterdam Neuroscience - Brain Imaging

Published
2022

13. OS03.6.A Rituximab in primary CNS lymphoma - long term follow-up of the phase III HOVON 105/ALLG NHL 24 Study

Author

Bromberg, J E C, primary, Issa, S, additional, van der Holt, B, additional, Minnema, M C, additional, Seute, T, additional, Durian, M F, additional, Cull, G, additional, van der Poel, M W M, additional, Stevens, W B C, additional, Zijlstra, J M, additional, Nijland, M, additional, Mason, K D, additional, Beeker, A, additional, Brandsma, D, additional, van den Bent, M J, additional, Gonzalez, M, additional, de Jong, D, additional, and Doorduijn, J K, additional

Published
2022
Full Text
View/download PDF

14. Cost-Effectiveness of Shortening Treatment Duration Based on Interim PET Outcome in Patients With Diffuse Large B-cell Lymphoma

Author

Greuter, M. J.E., Eertink, J. J., Jongeneel, G., Dührsen, U., Hüttmann, A., Schmitz, C., Lugtenburg, P. J., Barrington, S. F., Mikhaeel, N. G., Ceriani, L., Zucca, E., Carr, R., Györke, T., Burggraaff, C. N., de Vet, H. C.W., Hoekstra, O. S., Zijlstra, J. M., Coupé, V. M.H., Greuter, M. J.E., Eertink, J. J., Jongeneel, G., Dührsen, U., Hüttmann, A., Schmitz, C., Lugtenburg, P. J., Barrington, S. F., Mikhaeel, N. G., Ceriani, L., Zucca, E., Carr, R., Györke, T., Burggraaff, C. N., de Vet, H. C.W., Hoekstra, O. S., Zijlstra, J. M., and Coupé, V. M.H.

Abstract

Background: Guideline recommendations for diffuse large-B-cell lymphoma (DLBCL) treatment are shifting from long to short treatment duration, although it is still unclear whether shortening treatment duration does not cause any harm. As interim PET (I-PET) has high negative predictive value for progression, we evaluated the cost-effectiveness of shortening treatment duration dependent on I-PET result. Materials and Methods: We developed a Markov cohort model using the PET Re-Analysis (PETRA) database to evaluate a long treatment duration (LTD) strategy, ie 8x R-CHOP or 6x R-CHOP plus 2 R, and a short treatment duration (STD) strategy, ie 6x R-CHOP. Strategies were evaluated separately in I-PET2 positive and I-PET2 negative patients. Outcomes included total costs and quality-adjusted life-years (QALYs) per patient (pp) from a societal perspective. Net monetary benefit (NMB) per strategy was calculated using a willingness-to-pay threshold of €50,000/QALY. Robustness of model predictions was assessed in sensitivity analyses. Results: In I-PET2 positive patients, shortening treatment duration led to 50.4 additional deaths per 1000 patients. The STD strategy was less effective (-0.161 [95%CI: -0.343;0.028] QALYs pp) and less costly (-€2768 [95%CI: -€8420;€1105] pp). Shortening treatment duration was not cost-effective (incremental NMB -€5281). In I-PET2 negative patients, shortening treatment duration led to 5.0 additional deaths per 1000 patients and a minor difference in effectiveness (-0.007 [95%CI: -0.136;0.140] QALY pp). The STD strategy was less costly (-€5807 [95%CI: -€10,724;-€2685] pp) and led to an incremental NMB of €5449, indicating that it is cost-effective to shorten treatment duration. Robustness of these findings was underpinned by deterministic and probabilistic sensitivity analyses. Conclusion: Treatment duration should not be shortened in I-PET2 positive patients whereas it is cost-effective to shorten treatment duration in I-PET2 negative patients.

Published
2022

16. LONG‐TERM FOLLOW‐UP AND BIOMARKER ANALYSES OF BRENTUXIMAB VEDOTIN AND DHAP IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS: THE HOVON/LLPC TRANSPLANT BRAVE STUDY

Author

Driessen, J., primary, Kersten, M. J., additional, Visser, L., additional, den Berg, A., additional, Zijlstra, J. M., additional, Tonino, S. H., additional, Zwezerijnen, G. J., additional, Boellaard, R., additional, Lugtenburg, P. J., additional, Hutchings, M., additional, Nijland, M., additional, Liu, R. D., additional, Morschhauser, F., additional, Brice, P., additional, Gastinne, T., additional, Jong, D., additional, Hagenbeek, A., additional, Plattel, W. J., additional, and Diepstra, A., additional

Published
2021
Full Text
View/download PDF

17. PREDICTIVE VALUE OF QUANTITATIVE 18F‐FDG‐PET‐CT RADIOMICS ANALYSIS IN 174 PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA

Author

Driessen, J, primary, Zwezerijnen, G. J. C, additional, Schöder, H, additional, Moskowitz, A. J, additional, Kersten, M. J, additional, Moskowitz, C. H, additional, Eertink, J. J, additional, van de Brug, T, additional, de Vet, H. C. W, additional, Hoekstra, O. S, additional, Zijlstra, J. M., additional, and Boellaard, R, additional

Published
2021
Full Text
View/download PDF

18. Optimal timing and criteria of interim PET in DLBCL:a comparative study of 1692 patients

Author

Eertink, Jakoba J., Burggraaff, Coreline N., Heymans, M.W., Duhrsen, U, Huttmann, A, Schmitz, C, Muller, S, Lugtenburg, Elly, Barrington, S. F., Mikhaeel, N. G., Carr, R., Czibor, S., Györke, T., Ceriani, Luca, Zucca, E, Hutchings, M, Kostakoglu, L., Loft, A., Fanti, S., Wiegers, Sanne E., Pieplenbosch, Simone, Boellaard, R, Hoekstra, O.S., Zijlstra, J. M., de Vet, H.C.W., Eertink, Jakoba J., Burggraaff, Coreline N., Heymans, M.W., Duhrsen, U, Huttmann, A, Schmitz, C, Muller, S, Lugtenburg, Elly, Barrington, S. F., Mikhaeel, N. G., Carr, R., Czibor, S., Györke, T., Ceriani, Luca, Zucca, E, Hutchings, M, Kostakoglu, L., Loft, A., Fanti, S., Wiegers, Sanne E., Pieplenbosch, Simone, Boellaard, R, Hoekstra, O.S., Zijlstra, J. M., and de Vet, H.C.W.

Abstract

Interim 18F-fluorodeoxyglucose positron emission tomography (Interim- 18F-FDG-PET, hereafter I-PET) has the potential to guide treatment of patients with diffuse large B-cell lymphoma (DLBCL) if the prognostic value is known. The aim of this study was to determine the optimal timing and response criteria for evaluating prognosis with I-PET in DLBCL. Individual patient data from 1692 patients with de novo DLBCL were combined and scans were harmonized. I-PET was performed at various time points during treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. Scans were interpreted using the Deauville score (DS) and change in maximum standardized uptake value (DSUVmax ). Multilevel Cox proportional hazards models corrected for International Prognostic Index (IPI) score were used to study the effects of timing and response criteria on 2-year progression-free survival (PFS). I-PET after 2 cycles (I-PET2) and I-PET4 significantly discriminated good responders from poor responders, with the highest hazard ratios (HRs) for I-PET4. Multivariable HRs for a PET-positive result at I-PET2 and I-PET4 were 1.71 and 2.95 using DS4-5, 4.91 and 6.20 using DS5, and 2.93 and 4.65 using DSUVmax , respectively. DSUVmax identified a larger proportion of poor responders than DS5 did. For all criteria, the negative predictive value was >80%, and positive predictive values ranged from 30% to 70% at I-PET2 and I-PET4. Unlike I-PET1, I-PET3 discriminated good responders from poor responders using DS4-5 and DS5 thresholds (HRs, 2.94 and 4.67, respectively). I-PET2 and I-PET4 predict good response equally during R-CHOP therapy in DLBCL. Optimal timing and response criteria depend on the clinical context. Good response at I-PET2 is suggested for de-escalation trials, and poor response using DSUVmax at I-PET4 is suggested for randomiz

Published
2021

19. The eHealth self-management application ‘Oncokompas’ that supports cancer survivors to improve health-related quality of life and reduce symptoms:which groups benefit most?

Author

van der Hout, A., Holtmaat, K., Jansen, F., Lissenberg-Witte, B. I., van Uden-Kraan, C. F., Nieuwenhuijzen, G. A.P., Hardillo, J. A., Baatenburg de Jong, R. J., Tiren-Verbeet, N. L., Sommeijer, D. W., de Heer, K., Schaar, C. G., Sedee, R. J.E., Bosscha, K., van den Brekel, M. W.M., Petersen, J. F., Westerman, M., Honings, J., Takes, R. P., Houtenbos, I., van den Broek, W. T., de Bree, R., Jansen, P., Eerenstein, S. E.J., Leemans, C. R., Zijlstra, J. M., Cuijpers, P., van de Poll-Franse, L. V., Verdonck-de Leeuw, I. M., van der Hout, A., Holtmaat, K., Jansen, F., Lissenberg-Witte, B. I., van Uden-Kraan, C. F., Nieuwenhuijzen, G. A.P., Hardillo, J. A., Baatenburg de Jong, R. J., Tiren-Verbeet, N. L., Sommeijer, D. W., de Heer, K., Schaar, C. G., Sedee, R. J.E., Bosscha, K., van den Brekel, M. W.M., Petersen, J. F., Westerman, M., Honings, J., Takes, R. P., Houtenbos, I., van den Broek, W. T., de Bree, R., Jansen, P., Eerenstein, S. E.J., Leemans, C. R., Zijlstra, J. M., Cuijpers, P., van de Poll-Franse, L. V., and Verdonck-de Leeuw, I. M.

Abstract

Background: Oncokompas is a web-based self-management application that supports cancer survivors to monitor their health-related quality of life (HRQOL) and symptoms, and to obtain personalised feedback and tailored options for supportive care. In a large randomised controlled trial among survivors of head and neck cancer, colorectal cancer, and breast cancer and (non-)Hodgkin lymphoma, Oncokompas proved to improve HRQOL, and to reduce several tumour-specific symptoms. Effect sizes were however small, and no effect was observed on the primary outcome patient activation. Therefore, this study aims to explore which subgroups of cancer survivors may especially benefit from Oncokompas. Materials and methods: Cancer survivors (n = 625) were randomly assigned to the intervention group (access to Oncokompas, n = 320) or control group (6 months waiting list, n = 305). Outcome measures were HRQOL, tumour-specific symptoms, and patient activation. Potential moderators included socio-demographic (sex, age, marital status, education, employment), clinical (tumour type, stage, time since diagnosis, treatment modality, comorbidities), and personal factors (self-efficacy, personal control, health literacy, Internet use), and patient activation, mental adjustment to cancer, HRQOL, symptoms, and need for supportive care, measured at baseline. Linear mixed models were performed to investigate potential moderators. Results: The intervention effect on HRQOL was the largest among cancer survivors with low to moderate self-efficacy, and among those with high personal control and those with high health literacy scores. Cancer survivors with higher baseline symptom scores benefitted more on head and neck (pain in the mouth, social eating, swallowing, coughing, trismus), and colorectal cancer (weight) specific symptoms. Discussion: Oncokompas seems most effective in reducing symptoms in head and neck cancer and colorectal cancer survivors who report a higher burden of tumour-specific sym

Published
2021

20. The eHealth self-management application 'Oncokompas' that supports cancer survivors to improve health-related quality of life and reduce symptoms: Which groups benefit most?

Author

van der Hout, A., Holtmaat, K., Jansen, F., Lissenberg-Witte, B., Van Uden-Kraan, C. F., Nieuwenhuijzen, G. A. P., Hardillo, J. A., de Jong, R. J. Baatenburg, Tiren-Verbeet, N. L., Sommeijer, D. W., de Heer, K., Schaar, C. G., Sedee, R. J. E., Bosscha, K., van den Brekel, M. W. M., Petersen, F., Westerman, M., Honings, J., Takes, R. P., Houtenbos, null, van den Broek, W. T., de Bree, R., Jansen, P., Eerenstein, S. E. J., Leemans, C. R., Zijlstra, J. M., Cuijpersa, P., Van De Poll-Franse, L. V., Verdonck-de Leeuw, I. M., van der Hout, A., Holtmaat, K., Jansen, F., Lissenberg-Witte, B., Van Uden-Kraan, C. F., Nieuwenhuijzen, G. A. P., Hardillo, J. A., de Jong, R. J. Baatenburg, Tiren-Verbeet, N. L., Sommeijer, D. W., de Heer, K., Schaar, C. G., Sedee, R. J. E., Bosscha, K., van den Brekel, M. W. M., Petersen, F., Westerman, M., Honings, J., Takes, R. P., Houtenbos, null, van den Broek, W. T., de Bree, R., Jansen, P., Eerenstein, S. E. J., Leemans, C. R., Zijlstra, J. M., Cuijpersa, P., Van De Poll-Franse, L. V., and Verdonck-de Leeuw, I. M.

Abstract

BackgroundOncokompas is a web-based self-management application that supports cancer survivors to monitor their health-related quality of life (HRQOL) and symptoms, and to obtain personalised feedback and tailored options for supportive care. In a large randomised controlled trial among survivors of head and neck cancer, colorectal cancer, and breast cancer and (non-)Hodgkin lymphoma, Oncokompas proved to improve HRQOL, and to reduce several tumour-specific symptoms. Effect sizes were however small, and no effect was observed on the primary outcome patient activation. Therefore, this study aims to explore which subgroups of cancer survivors may especially benefit from Oncokompas.Materials and methodsCancer survivors (n = 625) were randomly assigned to the intervention group (access to Oncokompas, n = 320) or control group (6 months waiting list, n = 305). Outcome measures were HRQOL, tumour-specific symptoms, and patient activation. Potential moderators included socio-demographic (sex, age, marital status, education, employment), clinical (tumour type, stage, time since diagnosis, treatment modality, comorbidities), and personal factors (self-efficacy, personal control, health literacy, Internet use), and patient activation, mental adjustment to cancer, HRQOL, symptoms, and need for supportive care, measured at baseline. Linear mixed models were performed to investigate potential moderators.ResultsThe intervention effect on HRQOL was the largest among cancer survivors with low to moderate self-efficacy, and among those with high personal control and those with high health literacy scores. Cancer survivors with higher baseline symptom scores benefitted more on head and neck (pain in the mouth, social eating, swallowing, coughing, trismus), and colorectal cancer (weight) specific symptoms.DiscussionOncokompas seems most effective in reducing symptoms in head and neck cancer and colorectal cancer survivors who report

Published
2021

21. The eHealth self-management application ‘Oncokompas’ that supports cancer survivors to improve health-related quality of life and reduce symptoms: which groups benefit most?

Author

MS Hoofd-Hals Chirurgische Oncologie, Cancer, van der Hout, A., Holtmaat, K., Jansen, F., Lissenberg-Witte, B. I., van Uden-Kraan, C. F., Nieuwenhuijzen, G. A.P., Hardillo, J. A., Baatenburg de Jong, R. J., Tiren-Verbeet, N. L., Sommeijer, D. W., de Heer, K., Schaar, C. G., Sedee, R. J.E., Bosscha, K., van den Brekel, M. W.M., Petersen, J. F., Westerman, M., Honings, J., Takes, R. P., Houtenbos, I., van den Broek, W. T., de Bree, R., Jansen, P., Eerenstein, S. E.J., Leemans, C. R., Zijlstra, J. M., Cuijpers, P., van de Poll-Franse, L. V., Verdonck-de Leeuw, I. M., MS Hoofd-Hals Chirurgische Oncologie, Cancer, van der Hout, A., Holtmaat, K., Jansen, F., Lissenberg-Witte, B. I., van Uden-Kraan, C. F., Nieuwenhuijzen, G. A.P., Hardillo, J. A., Baatenburg de Jong, R. J., Tiren-Verbeet, N. L., Sommeijer, D. W., de Heer, K., Schaar, C. G., Sedee, R. J.E., Bosscha, K., van den Brekel, M. W.M., Petersen, J. F., Westerman, M., Honings, J., Takes, R. P., Houtenbos, I., van den Broek, W. T., de Bree, R., Jansen, P., Eerenstein, S. E.J., Leemans, C. R., Zijlstra, J. M., Cuijpers, P., van de Poll-Franse, L. V., and Verdonck-de Leeuw, I. M.

Published
2021

22. Cost-utility of an eHealth application 'Oncokompas' that supports cancer survivors in self-management: results of a randomised controlled trial

Author

CDL Patiëntenzorg KC, Anatomie, ZL Neuromusculaire Ziekten Zorg, MS Hoofd-Hals Chirurgische Oncologie, Cancer, van der Hout, A, Jansen, F, van Uden-Kraan, C F, Coupé, V M, Holtmaat, K, Nieuwenhuijzen, G A, Hardillo, J A, de Jong, R J Baatenburg, Tiren-Verbeet, N L, Sommeijer, D W, de Heer, K, Schaar, C G, Sedee, R J E, Bosscha, K, van den Brekel, M W M, Petersen, J F, Westerman, M, Honings, J, Takes, R P, Houtenbos, I, van den Broek, W T, de Bree, R, Jansen, P, Eerenstein, S E J, Leemans, C R, Zijlstra, J M, Cuijpers, P, van de Poll-Franse, L V, Verdonck-de Leeuw, I M, CDL Patiëntenzorg KC, Anatomie, ZL Neuromusculaire Ziekten Zorg, MS Hoofd-Hals Chirurgische Oncologie, Cancer, van der Hout, A, Jansen, F, van Uden-Kraan, C F, Coupé, V M, Holtmaat, K, Nieuwenhuijzen, G A, Hardillo, J A, de Jong, R J Baatenburg, Tiren-Verbeet, N L, Sommeijer, D W, de Heer, K, Schaar, C G, Sedee, R J E, Bosscha, K, van den Brekel, M W M, Petersen, J F, Westerman, M, Honings, J, Takes, R P, Houtenbos, I, van den Broek, W T, de Bree, R, Jansen, P, Eerenstein, S E J, Leemans, C R, Zijlstra, J M, Cuijpers, P, van de Poll-Franse, L V, and Verdonck-de Leeuw, I M

Published
2021

23. Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients

Author

Eertink, J. J., primary, Burggraaff, C. N., additional, Heymans, M. W., additional, Dührsen, U., additional, Hüttmann, A., additional, Schmitz, C., additional, Müller, S., additional, Lugtenburg, P. J., additional, Barrington, S. F., additional, Mikhaeel, N. G., additional, Carr, R., additional, Czibor, S., additional, Györke, T., additional, Ceriani, L., additional, Zucca, E., additional, Hutchings, M., additional, Kostakoglu, L., additional, Loft, A., additional, Fanti, S., additional, Wiegers, S. E., additional, Pieplenbosch, S., additional, Boellaard, R., additional, Hoekstra, O. S., additional, Zijlstra, J. M., additional, and de Vet, H. C. W., additional

Published
2021
Full Text
View/download PDF

24. F-18-FDG PET/CT baseline radiomics features are predictive of outcome in diffuse large B-cell lymphoma patients

Author

Eertink, J., van de Brug, T., Wiegers, S. E., Zwezerijnen, G. J. C., Pfaehler, E., Lugtenburg, P. J., van der Holt, B., de Vet, H. C. W., Hoekstra, O. S., Boellaard, R., Zijlstra, J. M., VU University medical center, APH - Methodology, Epidemiology and Data Science, Radiology and nuclear medicine, CCA - Imaging and biomarkers, Amsterdam Neuroscience - Brain Imaging, and Hematology

Published
2020

25. Aberrant patterns of PET-CT response for diffuse large B-cell lymphoma patients with MYC rearrangement

Author

Eertink, J., Celik, F., Huijbregts, J., Arens, A. I. J., Wiegers, S. E., Burggraaff, C. N., Hoekstra, O. S., Stroobants, S., Boellaard, R., de Vet, H. C. W., Chamuleau, M. E. D., Zijlstra, J. M., VU University medical center, Internal medicine, Radiology and nuclear medicine, CCA - Imaging and biomarkers, Amsterdam Neuroscience - Brain Imaging, Epidemiology and Data Science, APH - Methodology, and Hematology

Published
2020

26. Characteristics of the relationship between MTV and survival in diffuse large B-cell lymphoma - A PETRA consortium study

Author

Mikhaeel, N., Heymans, M. W., de Vet, H. C. W., Eertink, J. J., Boellaard, R., Duhrsen, U., Huttmann, A., Schmitz, C., Zucca, E., Hoekstra, O. S., Zijlstra, J. M., Barrington, S., Epidemiology and Data Science, APH - Methodology, APH - Personalized Medicine, VU University medical center, Radiology and nuclear medicine, Hematology, and CCA - Treatment and quality of life

Published
2020

27. Positron emission tomography guided omission of radiotherapy in early-stage unfavorable Hodgkin Lymphoma: Final results of the international, randomized Phase III HD17 trial by the German Hodgkin Study Group

Author

Borchmann, P., Kobe, C., Pluetschow, A., Greil, R., Meissner, J., Topp, M. S., Ostermann, H., Dierlamm, J., Mohm, J., Thiemer, J., Soekler, M., Kerkhoff, A., Ahlborn, M., Halbsguth, T., Martin, S., Keller, U., Balabanov, S., Pabst, T., Vogelhuber, M., Huettmann, A., Wilhem, M., Zijlstra, J. M., Moccia, A., Broeckelmann, P. J., von Tresckow, B., Fuchs, M., Eich, H., Baues, C., Hallek, M., Diehl, V, Dietlein, M., Engert, A., Borchmann, P., Kobe, C., Pluetschow, A., Greil, R., Meissner, J., Topp, M. S., Ostermann, H., Dierlamm, J., Mohm, J., Thiemer, J., Soekler, M., Kerkhoff, A., Ahlborn, M., Halbsguth, T., Martin, S., Keller, U., Balabanov, S., Pabst, T., Vogelhuber, M., Huettmann, A., Wilhem, M., Zijlstra, J. M., Moccia, A., Broeckelmann, P. J., von Tresckow, B., Fuchs, M., Eich, H., Baues, C., Hallek, M., Diehl, V, Dietlein, M., and Engert, A.

Published
2020

28. The eHealth self-management application ‘Oncokompas’ that supports cancer survivors to improve health-related quality of life and reduce symptoms: which groups benefit most?

Author

van der Hout, A., primary, Holtmaat, K., additional, Jansen, F., additional, Lissenberg-Witte, B. I., additional, van Uden-Kraan, C. F., additional, Nieuwenhuijzen, G. A. P., additional, Hardillo, J. A., additional, Baatenburg de Jong, R. J., additional, Tiren-Verbeet, N. L., additional, Sommeijer, D. W., additional, de Heer, K., additional, Schaar, C. G., additional, Sedee, R. J. E., additional, Bosscha, K., additional, van den Brekel, M. W. M., additional, Petersen, J. F., additional, Westerman, M., additional, Honings, J., additional, Takes, R. P., additional, Houtenbos, I., additional, van den Broek, W. T., additional, de Bree, R., additional, Jansen, P., additional, Eerenstein, S. E. J., additional, Leemans, C. R., additional, Zijlstra, J. M., additional, Cuijpers, P., additional, van de Poll-Franse, L. V., additional, and Verdonck-de Leeuw, I. M., additional

Published
2020
Full Text
View/download PDF

29. Treatment of Older Patients with Mantle-Cell Lymphoma

Author

Kluin-Nelemans, H. C., Hoster, E., Hermine, O., Walewski, J., Trneny, M., Geisler, C. H., Stilgenbauer, S., Thieblemont, C., Vehling-Kaiser, U., Doorduijn, J. K., Coiffier, B., Forstpointner, R., Tilly, H., Kanz, L., Feugier, P., Szymczyk, M., Hallek, M., Kremers, S., Lepeu, G., Sanhes, L., Zijlstra, J. M., Bouabdallah, R., Lugtenburg, P. J., Macro, M., Pfreundschuh, M., Procházka, V., Di Raimondo, F., Ribrag, V., Uppenkamp, M., André, M., Klapper, W., Hiddemann, W., Unterhalt, M., and Dreyling, M. H.

Published
2012
Full Text
View/download PDF

30. Cost-utility of an eHealth application ‘Oncokompas’ that supports cancer survivors in self-management: results of a randomised controlled trial

Author

van der Hout, A., primary, Jansen, F., additional, van Uden-Kraan, C. F., additional, Coupé, V. M., additional, Holtmaat, K., additional, Nieuwenhuijzen, G. A., additional, Hardillo, J. A., additional, de Jong, R. J. Baatenburg, additional, Tiren-Verbeet, N. L., additional, Sommeijer, D. W., additional, de Heer, K., additional, Schaar, C. G., additional, Sedee, R. J. E., additional, Bosscha, K., additional, van den Brekel, M. W. M., additional, Petersen, J. F., additional, Westerman, M., additional, Honings, J., additional, Takes, R. P., additional, Houtenbos, I., additional, van den Broek, W. T., additional, de Bree, R., additional, Jansen, P., additional, Eerenstein, S. E. J., additional, Leemans, C. R., additional, Zijlstra, J. M., additional, Cuijpers, P., additional, van de Poll-Franse, L. V., additional, and Verdonck-de Leeuw, I. M., additional

Published
2020
Full Text
View/download PDF

31. Treatment with 2 cycles of BEACOPPesc followed by 2 cycles of ABVD and IF-RT is superior to 4 cycles of ABVD and IF-RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 trial: V336

Author

Engert, A., Borchmann, P., Plütschow, A., Fuchs, M., Markova, J., Lohri, A., Kral, Z., Greil, R., Topp, M. S., Villalobos, M., Zijlstra, J. M., Söckler, M., Wingbermühle, K., Stein, H., Eich, H.-T., Müller, R.-P., and Diehl, V.

Published
2009

34. Pet positivity after 2 cycles of abvd is a risk factor in patients with early-stage favorable Hodgkin lymphoma treated in the phase 3 GHSG HD16 study

Author

Fuchs, M., Görgen, H., Kobe, C., Kuhnert, G., Hitz, F., Greil, R., Sasse, S., Topp, M. S., Schäfer, E., Hertenstein, B., Sökler, M., Vogelhuber, M., Zijlstra, J. M., Keller, U. B., Krause, S. W., Wilhelm, M., Maschmeyer, G., Thiemer, J., Dührsen, U., Meissner, J., Viardot, A., Eich, H., Baues, C., Diehl, V., Rosenwald, A., Tresckow, Bastian von, Dietlein, M., Borchmann, P., and Engert, A.

Subjects
Medizin
Published
2019

35. Image Reconstruction Robustness of Radiomic Features in Lymphoma FDG PET/CT studies

Author

Zwezerijnen, G. J. C., Burggraaff, C. N., Koopman, T., Zijlstra, J. M., Pieplenbosch, S., Eertink, J. J., Hoekstra, O. S., Boellaard, R., Radiology and nuclear medicine, Hematology laboratory, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, CCA - Cancer Treatment and quality of life, Hematology, VU University medical center, Amsterdam Neuroscience - Brain Imaging, and ACS - Heart failure & arrhythmias

Published
2018

36. BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL.

Author

Borchmann, P., Moccia, A. A., Greil, R., Schneider, G., Hertzberg, M., Schaub, V., Hüttmann, A., Keil, F., Dierlamm, J., Hänel, M., Novak, U., Meissner, J., Zimmermann, A., Mathas, S., Zijlstra, J. M., Fosså, A., Viardot, A., Hertenstein, B., Martin, S., and Giri, P.

Subjects
CLINICAL trials, HODGKIN'S disease
Abstract

B Introduction: b Individualized, PET2-guided first-line treatment of patients with advanced-stage classical Hodgkin Lymphoma (AS-cHL) with eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) achieves outstanding survival outcomes, but also causes relevant treatment-related morbidity (TRMB). This mature and unparalleled PFS rate suggests that individualized treatment with PET2-directed BrECADD is currently the most effective therapy for adult patients with AS-cHL. BRECADD IS NON-INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL. [Extracted from the article]

Published
2023
Full Text
View/download PDF

37. Toxicities at one year follow‐up in patients with advanced stage classical Hodgkin Lymphoma: results from the randomized phase III HD21 trial by the German Hodgkin Study Group.

Author

Ferdinandus, J., Moccia, A. A., Greil, R., Hertzberg, M., Schaub, V., Hüttmann, A., Keil, F., Dierlamm, J., Hänel, M., Novak, U., Meissner, J., Zimmermann, A., Mathas, S., Zijlstra, J. M., Fosså, A., Viardot, A., Hertenstein, B., Martin, S., Giri, P., and Kamper, P.

Subjects
CLINICAL trials, HODGKIN'S disease
Abstract

At FU12, grade 2 or higher PNP was reported for 17 (2.7%) patients following eBEACOPP and for 12 (1.9%) patients following BrECADD; however, no or only grade 1 PNP was reported for most patients in both treatment groups with 97.3% for eBEACOPP and 98.1% for BrECADD. B Introduction: b The HD21 trial compares BrECADD with eBEACOPP for the first-line treatment of advanced stage classical Hodgkin Lymphoma (AS-cHL). FSH levels at FU12 were available for 597 patients and were higher for patients who received eBEACOPP (mean FSH 29.4 and 31.8 after 4 and 6 cycles, respectively) compared to BrECADD (mean FSH 18.3 and 20.5 after 4 and 6 cycles, respectively. [Extracted from the article]

Published
2023
Full Text
View/download PDF

38. Impact of PET‐2 guided treatment de‐escalation on time‐to‐recovery from cancer‐related fatigue in advanced stage Hodgkin Lymphoma: results from the GHSG HD18 study.

Author

Ferdinandus, J., Müller, H., Damaschin, C., Jacob, A. S., Meissner, J., Krasniqi, F., Mey, U., Schöndube, D., Thiemer, J., Mathas, S., Zijlstra, J. M., Greil, R., Feuring‐Buske, M., Markova, J., Kobe, C., Eich, H. T., Baues, C., Fuchs, M., Behringer, K., and Borchmann, P.

Subjects
HODGKIN'S disease, CANCER fatigue
Abstract

B Introduction: b Persisting cancer related fatigue (CRF) has impact on health related quality of life (HRQoL) and social re-integration of patients with Hodgkin lymphoma (HL). Impact of PET-2 guided treatment de-escalation on time-to-recovery from cancer-related fatigue in advanced stage Hodgkin Lymphoma: results from the GHSG HD18 study The GHSG HD18 trial established treatment PET-2 guided de-escalation of treatment for advanced-stage HL as new standard. [Extracted from the article]

Published
2023
Full Text
View/download PDF

39. Differences in baseline PET/CT lymphoma distribution patterns between DLBCL‐NOS and high‐risk DLBCL patients.

Author

Croese, K. J., Zwezerijnen, G. J. C., Bes, A. L., Wiegers, S. E., Heymans, M. W., Boellaard, R., Lugtenburg, P. J., Eertink, J. J., Zijlstra, J. M., and Chamuleau, M. E. D.

Subjects
DIFFUSE large B-cell lymphomas, LYMPHOMAS
Abstract

B Introduction: b Approximately 8%-10% of diffuse large B-cell lymphoma (DLBCL) patients have genetic aberrations, known as high grade B-cell lymphoma double-hit and triple-hit (HGBL-DH/TH, with I MYC/BCL2 i and I MYC/BCL2/BCL6 i rearrangements). B Conclusions: b DLBCL-NOS and HGBL show a remarkably different distribution pattern on baseline PET/CT, with significant differences in nodal- and extranodal localizations, and a higher MTV and number of extranodal sites in HGBL. Differences in baseline PET/CT lymphoma distribution patterns between DLBCL-NOS and high-risk DLBCL patients. [Extracted from the article]

Published
2023
Full Text
View/download PDF

40. TREATMENT REDUCTION IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA AND NEGATIVE INTERIM PET: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 TRIAL HD18 BY THE GERMAN HODGKIN STUDY GROUP

Author

Borchmann, P., Goergen, H., Kobe, C., Fuchs, M., Greil, R., Zijlstra, J. M., Huettmann, A., Markova, J., Meissner, J., Feuring-Buske, M., Bentz, M., Dierlamm, J., Kuehnhardt, D., Lohri, A., Novak, U., Eichenauer, D., Eich, H., Baues, C., Stein, H., Diehl, V., Kuhnert, G., Dietlein, M., Engert, A., Borchmann, P., Goergen, H., Kobe, C., Fuchs, M., Greil, R., Zijlstra, J. M., Huettmann, A., Markova, J., Meissner, J., Feuring-Buske, M., Bentz, M., Dierlamm, J., Kuehnhardt, D., Lohri, A., Novak, U., Eichenauer, D., Eich, H., Baues, C., Stein, H., Diehl, V., Kuhnert, G., Dietlein, M., and Engert, A.

Published
2017

44. PLASMA VESICLE-ASSOCIATED miRNAs AS THERAPY RESPONSE BIOMARKERS IN HODGKIN LYMPHOMA

Author

Pegtel, D. M., Drees, E., Eijndhoven, M. A. J., Groenewegen, N. J., Niele, S., Prins, R., Baglio, S. R., Zijlstra, J. M., Voorn, H., Libregts, Sfwm, Wauben, M. H., Menezes, R. X., Weering, J. R. T., Nieuwland, R., Diepstra, A., Anke van den Berg, Jong, D., Pathology, CCA - Biomarkers, Hematology, Clinical genetics, Amsterdam Neuroscience - Cellular & Molecular Mechanisms, Pediatrics, and Surgery

Published
2016

47. First-line treatment and survival of transformed follicular lymphoma in the netherlands in the rituximab era; a population-based analysis

Author

Wondergem, M J, Issa, D E, Zijlstra, J M, Visser, O, Zweegman, S, Chamuleau, M E, Hematology, CCA - Innovative therapy, CCA - Disease profiling, and CCA - Quality of life

Subjects
hemic and lymphatic diseases
Abstract

Introduction: Treatment of transformed follicular lymphoma (TFL) is diverse as there are no randomized studies to guide therapy. Patients are treated with rituximab (R)-chemotherapy only or with R-chemo and upfront autologous stem cell transplantation (ASCT) at their physicians' discretion. We investigated different treatment modalities and outcome of patients registered in the Population-based Haematological Registry for Observational Studies (PHAROS), covering 40% of the Dutch population. Methods: From the PHAROS registry, we extracted all patients with a diagnosis of both follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) between January 2004 and July 2013 and checked their histology. Only patients with biopsy-proven DLBCL and underlying FL (previously or simultaneously diagnosed) were included. A separate analysis was performed on patients below 68 years, since upfront ASCT was given up to 67 years. Results: One hundred and sixty-one patients were included, median age at transformation was 63 years (34-91), median time to TFL was 14 months (0-101) and median follow-up after transformation was 17 months (1-111). Former treatment for FL: Sixty-one per cent had been treated with chemotherapy for FL (66% of them with R), 2% had received radiotherapy only, 24% were under a watch-and-wait strategy and, in 13%, FL and DLBCL were diagnosed simultaneously. Treatment for TFL: Ten patients were unable to receive any treatment. All 151 treated patients received R-chemo as induction therapy: 62 patients (33

Published
2015

48. Lymfoïde maligniteiten: de WHO-classificatie en algemene principes

Author

Kluin, Philip, Veelken, J. Hendrik, Zijlstra, J. M., Löwenberg, Bob, Ossenkoppele, Gert, Blijlevens, Nicole, Leebeek, Frank, Zweegman, Sonja, and Stem Cell Aging Leukemia and Lymphoma (SALL)

Abstract

Het terrein van de klinische hematologie bestrijkt een fascinerend palet van aan­doe­nin­gen dat uitwaaiert van zeldzame aan­ge­bo­ren ziekten, via veel voorkomende ziekten zoals trombose en anemie, tot een gevarieerd scala aan kwaadaardige ziekten van bloed, beenmerg en lymfklieren met een zeer pluriform beloop. De hematoloog bedient zich heden ten dage van geavanceerde, specialistische diagnostiek en steunt op een divers arsenaal van therapeutische benaderingen zoals bloedtransfusie, antistolling, stamceltransplantatie, immunotherapie, doelgerichte therapie op moleculaire aangrijpingspunten en chemotherapie in grote verscheidenheid. Het veld van de hematologie over de volle breedte is meer dan ooit in beweging en er voltrekken zich op bijna elk onderdeel van het vakgebied belangwekkende ontwikkelingen. Vele van deze ontwikkelingen bieden wezenlijk nieuwe inzichten in de mechanismen van hematologische processen en de biologische basis van hematologische ziekten. Sommige ontwikkelingen markeren doorbraken in de patiëntenzorg. Zij creëren verbeterde therapeutische perspectieven. Samen bepalen deze ontwikkelingen de klinische praktijk van de behandeling van de patiënt met een hematologische aandoening van vandaag. Het Leerboek hematologie heeft in het veld zijn plaats ingenomen als een gezaghebbend standaardwerk. Hematologie is bij uitstek een multidisciplinair vakgebied. Niet alleen de klinisch hematoloog houdt zich bezig met hematologische ziekten. Ook de patholoog, de klinisch geneticus, de immunoloog, de viroloog, de microbioloog, de radioloog en de nucleair geneeskundige doen dat in hun dagelijks werk. Medisch specialisten binnen verschillende vakgebieden hebben niet zelden ‘translationeel’ te maken met het vak van de hematologie, en dat geldt niet minder voor de generalistisch georiënteerde internist, kinderarts en huisarts. Zij allen kunnen op overzichtelijke wijze terecht bij dit boek dat een up-to-date naslagwerk verschaft op het terrein van de bloedziekten. Dankzij de uitmuntende bijdragen van een keur van gezaghebbende auteurs met uiteenlopende gespecialiseerde achtergrond, presenteren wij een hoogwaardig Leerboek hematologie, dat met deze nieuwe druk geheel is geactualiseerd. Het boek wordt ondersteund met een website waarop het volledige boek digitaal raadpleegbaar is en waar aanvullende informatie te vinden is. 'Het Leerboek Hematologie kan behalve als leerboek ook uitstekend als naslagwerk dienstdoen. Het is detaillistisch en tegelijkertijd overzichtelijk en is zo voor zowel artsen in de eerste als de tweede lijn zeer geschikt.' - Medisch Contact, maart 2015.

Published
2015

49. Risk of male breast cancer after Hodgkin lymphoma

Author

de Vries, Simone, Krul, Inge M., Schaapveld, Michael, Janus, Cecile P. M., Rademakers, Saskia E., Roesink, Judith M., Nijziel, Marten R., Bilgin, Yavuz M., van Leeuwen, F. E., Nijdam, A., Aleman, B. M. P., de Boer, J. P., Janus, C. P. M., Mutsaers, P. G. N. J., So-Osman, C., Zijlstra, J. M., Meijer, O. W. M., Rademakers, S. E., Krol, A. D. G., Kersten, M. J., Tonino, S. H., Jalink, M., Daniëls, L. A., van Spronsen, D. J., van der Maazen, R. W. M., Loonen, J., Roesink, J. M., Oostvogels, R., de Weijer, R., Buter, D., de Boer, A., Aarsman, K. M., Oudbier, C. W., Nijziel, M. R., van den Berg, M., Verschueren, K., Schippers, M., Boersma, R. S., Issa, D. E., Plattel, W. J., Stedema, F. G., Koene, H. R., Raymakers, E. R. P. M., Schimmel, E., van Hezewijk, M., Bouma, P., Muller, K., Siemes, C., van der Spek, J. M., Ong, F., Jonkman, A., de Jongh, E., Sprangers, S., Kortleve, J. P., Vermeiden, C. M., Ta, B., Vercoulen, L., Paulissen, J., Posthuma, E. F. M., Brouwer, R. E., Soechit, S., van der Wiel, M., Böhmer, L., Bilgin, M. Y., Kuipers, S., Houmes, M., te Boome, L., Gommers, S., Aleman, Berthe M. P., and van Leeuwen, Flora E.

Abstract

•Male survivors of HL treated with chest radiotherapy have an increased risk of developing BC compared with the general population.•Although the occurrence of male BC is an uncommon event, clinicians should be alert to BC symptoms in male survivors of HL.

Published
2024
Full Text
View/download PDF

50. AN UPDATE ON BETER, THE DUTCH NATIONWIDE SURVIVORSHIP CARE PROGRAMME FOR HODGKIN LYMPHOMA SURVIVORS

Author

Poli Van Creveldkliniek Medisch, Verpleegkundig Specialisten, Cancer, Nijdam, A., Aleman, B. M. P., van' t Veer, M. B., Janus, C. P. M., de Weijer, R., Danils, L. A., Stedema, F. G., Zijlstra, J. M., van der Maazen, R. W. M., Borger, J. H., Verschueren, K., Manenschijn, J., Posthuma, E. F. M., Raemaekers, J., van Leeuwen, F. E., Poli Van Creveldkliniek Medisch, Verpleegkundig Specialisten, Cancer, Nijdam, A., Aleman, B. M. P., van' t Veer, M. B., Janus, C. P. M., de Weijer, R., Danils, L. A., Stedema, F. G., Zijlstra, J. M., van der Maazen, R. W. M., Borger, J. H., Verschueren, K., Manenschijn, J., Posthuma, E. F. M., Raemaekers, J., and van Leeuwen, F. E.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results